Pectin supplementation in MASLD: A randomized study protocol on inflammation, microbiome, and metabolic health
تأثير مكمل البكتين في MASLD: بروتوكول عشوائي يقيّم الالتهاب والميكروبيوم والصحة الأيضية
Journal: PloS one
University: University of Nottingham
Study Type: RCT
Evidence Level: preliminary
Participants: 30
Published:
⚠️ Warning: This is a preliminary study (animal/cell) and has not been proven in humans.
30-Second Summary
This study protocol outlines a single-centre, double-blind, randomized, placebo-controlled trial to test whether pectin supplementation modulates systemic inflammation, the gut microbiome, and metabolic health in MASLD patients. The trial plans to enroll 30 adults with MASLD and compare pectin to placebo over the intervention period.
1-Minute Summary
The protocol describes a single-centre, double-blind, randomized, placebo-controlled dietary intervention evaluating the impact of pectin on systemic inflammation, gut microbiome, and metabolic health in MASLD. Thirty adults with MASLD will be randomized 1:1 to receive either pectin or placebo. Primary outcomes include systemic inflammatory markers, microbiome composition, and metabolic health parameters. As a protocol, no results are yet available; findings will inform feasibility and potential mechanisms for dietary fiber in MASLD.
3-Minute Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Emerging evidence suggests dietary fibre, particularly pectin, may improve metabolic health by modulating systemic inflammation, gut microbiota, and intestinal permeability. However, controlled human data in MASLD are limited. This study protocol outlines a single-centre, double-blind, randomised, placebo-controlled dietary intervention to evaluate the effects of pectin supplementation on inflammatory pathways, the gut microbiome, and metabolic health in MASLD patients. The trial will be conducted at Nottingham University Hospitals NHS Trust in partnership with the University of Nottingham. Thirty adults with MASLD will be randomised 1:1 to receive either pectin or an isocaloric placebo for the intervention period (exact duration to be specified in the protocol). Primary outcomes include changes in systemic inflammatory markers (e.g., hs-CRP, IL-6, TNF-α). Secondary outcomes cover gut microbiome composition and function (through sequencing approaches) and measures of metabolic health (lipid profile, glucose tolerance, insulin resistance, liver fat indices). Exploratory analyses will examine associations between inflammation, microbial shifts, and metabolic changes. No results are available yet, as this is a study protocol. Findings should inform feasibility, estimate effect sizes, and guide planning for larger trials. The protocol emphasizes adherence, safety, and blinding integrity.
Full Analysis
This protocol presents a scientifically plausible approach to address the gut–liver axis in MASLD by testing whether pectin supplementation can modulate key inflammatory pathways, microbiome characteristics, and metabolic health markers. The study adopts a robust double-blind, randomised, placebo-controlled design, which reduces biases related to treatment expectation and selection. Conducting the trial at a single centre with a clearly defined MASLD cohort enhances internal validity and standardises procedures, though it may limit external generalizability. Primary outcomes target systemic inflammation (e.g., hs-CRP, IL-6, TNF-α), aligning with MASLD pathophysiology where low-grade inflammation is implicated. Secondary outcomes probe gut microbiome composition and function via sequencing approaches, plus metabolic health indices such as lipid panels, glucose tolerance, and hepatic fat measures; this integrated, multi-omics-like approach may enable exploration of potential mechanistic links between fiber fermentation products (e.g., short-chain fatty acids) and host metabolic responses. A key strength is the isocaloric placebo control, which helps isolate the effects of pectin independent of caloric differences. Potential weaknesses include a small sample size (n=30), which may limit statistical power and subgroup analyses. Dietary adherence and background physical activity could confound results; rigorous monitoring and pre-specification of analysis plans will be essential. Microbiome data are susceptible to technical variability, necessitating careful sample handling and bioinformatics. No results exist yet; the study may yield feasibility data and preliminary effect size estimates to inform larger trials and design refinements.Health Implications
If signals emerge that pectin may modulate inflammation or the gut microbiome in MASLD, incorporating more fiber-rich foods into daily meals could be reasonable as part of a balanced diet. Practical steps include adding a variety of fruits, vegetables, whole grains, and legumes gradually to increase fiber intake while monitoring tolerance. Regular physical activity and maintaining a healthy weight remain important. Any dietary changes should be discussed with a clinician, especially for individuals with liver disease or comorbidities. The study’s findings may help shape future dietary guidance and the design of larger trials, but should not be interpreted as clinical recommendations until validated.
Key Findings
- No results yet as this is a study protocol.
- Aims include evaluating inflammation, microbiome, and metabolic health outcomes.